> ## Content Index > Fetch the complete content index at: https://www.foodconsumer.org/llms.txt > Use this file to discover other available public pages before exploring further. # GcMAF: A Scientific and Clinical Review - URL: https://www.foodconsumer.org/gcmaf-a-scientific-and-clinical-review/ - Published: 2026-10-24T15:10:08.000Z - Updated: 2026-10-24T17:35:27.000Z - Author: xiaohong ma - Tags: Cancer Editor's note: The academic literature is not absolutely unbiased or factually correct, given that research and the publication of research reports are controlled by human beings, and intrinsic conflicts of interest can influence the nature of any report—including this review. Readers are advised to keep an open mind, learn as much as they can, and then make an informed judgment for themselves. --- # # GcMAF: A Scientific and Clinical Review A critical review of Gc protein-derived macrophage-activating factor: its mechanisms of action, therapeutic potential, clinical research, safety and regulatory status | October 2026 ## Executive Summary GcMAF (Gc protein-derived macrophage-activating factor) is an experimental immunomodulatory protein derived from vitamin D-binding protein (VDBP), a protein that occurs naturally in human blood. It has drawn scientific interest because of its reported ability to influence macrophages, the immune cells that detect pathogens, clear damaged cells, regulate inflammation and respond to tumors. Over several decades, researchers have asked whether it could be used to treat cancer, infectious diseases, immune dysfunction and inflammatory disorders. Early laboratory studies showed increased macrophage activity after exposure to certain GcMAF preparations, and preliminary clinical reports described possible improvements in patients with advanced cancer. These observations remain controversial. The studies behind them had serious methodological weaknesses, lacked adequate control groups and relied on a biomarker of uncertain meaning, and several of the most influential papers have since been retracted. In short, GcMAF has shown biological activity in some experimental systems, but rigorous clinical trials have not established it as a treatment for any human disease. Cancer Research UK and Cancer Council Australia have both concluded that there is no convincing evidence supporting its use against cancer \[8, 9\]. ### Overall evidence assessment | Area | Assessment | | ---------------------------------- | --------------------------------------------------------- | | Biological rationale | Plausible but incompletely established | | Laboratory macrophage activation | Demonstrated in some experimental systems | | Animal studies | Preliminary findings | | Human cancer treatment | Insufficient reliable evidence | | HIV and other infections | Unproven clinical benefit | | Autism and neurological conditions | No established therapeutic efficacy | | Long-term safety | Inadequately characterised | | Regulatory approval | Not an approved cancer treatment | | Future research | Scientifically possible, but requires rigorous validation | The evidence does not show that GcMAF is ineffective in every setting, nor does it confirm the benefits claimed for it. GcMAF remains an investigational approach, with major uncertainties about its mechanism, clinical activity, safety and reproducibility. ## 1\. What is GcMAF? Understanding the claims made for GcMAF requires some background on vitamin D-binding protein, the sugar chains attached to proteins, and how macrophages work. ### 1.1 Vitamin D-binding protein Vitamin D-binding protein, also called DBP, Gc-globulin or group-specific component, is a multifunctional plasma protein made mainly in the liver. It carries vitamin D metabolites through the bloodstream, binds actin released from injured tissue, and takes part in inflammation and immune regulation. Some forms of the protein carry carbohydrate chains attached to the protein backbone. This glycosylation can affect a protein's structure and function. The GcMAF hypothesis holds that trimming these carbohydrate chains in a particular way produces a form of the protein that boosts macrophage activity. ### 1.2 Formation of GcMAF Nobuto Yamamoto and colleagues proposed that vitamin D-binding protein could be converted into a macrophage-activating factor by two enzymes: β-galactosidase, which removes certain galactose residues, and sialidase (neuraminidase), which removes terminal sialic acid. The product was described as carrying a single remaining N-acetylgalactosamine (GalNAc) residue. A 1996 paper in *Molecular Immunology* reported that enzymatically prepared GcMAF increased macrophage phagocytic activity in mice, and this work laid the early groundwork for later studies \[1\]. Even so, the exact molecular identity of active GcMAF preparations, how consistent they are from batch to batch, and whether the proposed mechanism works in humans as described are all still open questions. Even the shape of the sugar chain has been revised. Yamamoto's original model placed galactose and sialic acid on the GalNAc in a branched arrangement; mass spectrometry has since shown the three sugars to be arranged in a line, with GalNAc attached to the threonine and galactose and sialic acid added in turn \[12\]. The three common human variants also differ: Gc1F and Gc1S both carry the trisaccharide at Thr420, while Gc2 has a lysine in that position and is not glycosylated there at all. ## 2\. How GcMAF Is Proposed to Work ### 2.1 Macrophage activation Macrophages are found throughout the body. They clear cellular debris, engulf microorganisms, present antigens to other immune cells, release signaling molecules and support tissue repair. They also play a part in cancer, where, depending on their state and surroundings, they can either fight or assist tumor growth. GcMAF is thought to change macrophage behavior by increasing phagocytosis, altering cell signaling and modifying the immune response to abnormal cells. The proposed sequence is: **Vitamin D-binding protein → enzymatic removal of sugar residues → GcMAF → altered macrophage activity → effects on immune surveillance and inflammatory signaling** This is a hypothesis about mechanism. It says nothing, on its own, about whether GcMAF works as a treatment in people. ### 2.2 Changes in phagocytic activity Phagocytosis is the process by which immune cells engulf and digest particles, microbes or cell fragments. Several experiments found that macrophages became more phagocytic after exposure to GcMAF, which matters because this function contributes to immune defense. Three caveats apply. A rise in phagocytosis in a laboratory assay does not necessarily lead to better disease outcomes. More macrophage activity is not always good: excessive or misdirected activation can damage tissue and drive inflammation. And macrophages work within a wider network of immune cells, cytokines, blood vessels and tissue signals, so their behavior cannot be explained by one activating protein. GcMAF's effects need to be studied in the context of the whole immune system, not judged from isolated macrophage measurements. ### 2.3 Effects on cancer cells Interest in GcMAF for cancer grew partly from the observation that macrophages can help recognize and destroy malignant cells, and some laboratory work suggests certain preparations change how macrophages respond in cancer models. One result complicates the standard account of how GcMAF is supposed to work. In a 2020 study, Gc2, which carries no sugar at position 420, still increased phagocytic activity in macrophage-like cells, and its dose response resembled that of the glycosylated Gc1F and Gc1S forms \[12\]. If the exposed GalNAc residue is what macrophages recognize, a protein lacking it should have been inert. The authors suggested that the sugar may act as a recognition marker that triggers a protein-to-protein interaction rather than as the active signal itself, and noted that people homozygous for Gc2, who cannot make GalNAc-bearing GcMAF, do not appear to be at higher risk of cancer. Whichever explanation holds, the mechanism is less settled than the standard description implies. Tumor-associated macrophages, however, are a mixed population. Some support antitumor immunity; others promote tumor growth, blood-vessel formation, immune suppression and metastasis. The assumption that activating macrophages will reliably destroy tumours is therefore too simple. A GcMAF-based cancer treatment would have to show measurable, reproducible antitumor effects with acceptable safety, not just immune activation. ## 3\. GcMAF and the Nagalase Hypothesis Much of the GcMAF literature centers on the enzyme alpha-N-acetylgalactosaminidase, usually called nagalase. ### 3.1 What is nagalase? Nagalase cleaves particular carbohydrate structures. Early GcMAF researchers proposed that some cancers and infections raise nagalase activity, which strips vitamin D-binding protein of the sugar needed to make macrophage-activating factor and so weakens macrophage responses. Giving GcMAF directly was supposed to get around this problem. ### 3.2 Nagalase as a proposed disease biomarker Several early clinical studies used falling serum nagalase activity as their measure of response, on the reasoning that lower activity meant less tumour or better immune function. This approach has been heavily criticized. Nagalase is not a validated marker for monitoring cancer treatment, and a change in its activity cannot on its own show that a tumor has shrunk or disappeared. Cancer Research UK pointed out how hard it is to interpret studies that reported falling nagalase without reliable clinical evidence of tumor response \[8\]. ### 3.3 Why the distinction matters A laboratory marker can change for many reasons without any real clinical improvement; a patient's enzyme level might fall while the disease continues to progress. Validating a biomarker means showing that it reliably reflects a clinically important condition or outcome under defined circumstances. Nagalase has not met that standard, and it should not replace imaging, pathology, disease-specific tests or survival analysis. A more recent review of nagalase in cancer also raises doubts about the proposed enzyme mechanism and the interpretation of the earlier findings. The nagalase hypothesis is still being investigated, but nagalase testing is not clinically established as a way to diagnose cancer, measure tumor burden or show that GcMAF works. ## 4\. Clinical Research on GcMAF in Cancer Cancer has been the most prominent and most disputed use of GcMAF. Several papers claimed promising results in breast, colorectal, prostate and other cancers, but their quality varies widely and some of the most influential have been retracted. ### 4.1 Early breast cancer research In 2008, Yamamoto and colleagues reported in the *International Journal of Cancer* on 16 patients with metastatic breast cancer given weekly GcMAF injections. They described falling nagalase activity and long periods without recurrence. The idea that a small dose of a naturally derived protein could affect advanced cancer attracted a good deal of attention. The study had no randomized comparison group, leaned heavily on an unvalidated biomarker and lacked the rigorous assessment of disease response needed to support its conclusions. It was retracted in 2014 over irregularities in its institutional review board approval documents \[2\]. A retraction for ethics paperwork does not prove the data were fabricated, but it does mean the paper cannot be treated as reliable evidence of benefit. ### 4.2 Colorectal cancer research A second paper described eight patients previously treated for colorectal cancer. The authors reported falling nagalase activity during GcMAF treatment and took this as evidence that residual metastatic disease had been eliminated. The difficulty is that a change in an experimental enzyme marker was treated as proof of cure. The patients had no metastatic disease visible on CT at baseline; their supposed tumor burden was inferred from nagalase levels alone. Without documented active disease and a control group, there is no way to tell whether GcMAF eliminated cancer, whether earlier treatment had already done so, or whether the marker changes had anything to do with the tumour. This paper was also retracted in 2014 for institutional review board irregularities \[3\]. ### 4.3 Prostate cancer research A third paper described GcMAF treatment in 16 men with prostate cancer and again reported falling nagalase activity. It had no randomized controls, and its conclusions sometimes rested on nagalase values even when prostate-specific antigen (PSA) did not change. PSA is an imperfect marker, but a claim to have eliminated cancer needs supporting evidence, not the dismissal of conflicting standard measurements without good reason. The paper matters to the history of GcMAF research but does not show that GcMAF cures prostate cancer \[4\]. ### 4.4 A 2013 retrospective study of advanced cancer A 2013 report in *OncoImmunology* looked back at 20 patients with various advanced cancers who had received GcMAF. Nagalase activity fell in 19 of them, and the authors described some clinical improvements. They also acknowledged that the analysis was retrospective and uncontrolled and could not establish cause and effect \[6\]. That admission is important. An uncontrolled retrospective study can generate hypotheses, but it cannot separate a treatment's effect from prior or concurrent care, natural variation, selective reporting or changes in the disease itself. The study offers preliminary observations, not proof of efficacy. ### 4.5 Comparative overview of influential studies | Study | Participants | Main reported finding | Critical limitation | | -------------------------------------------- | ------------ | ------------------------------------------ | -------------------------------------------------------- | | Yamamoto et al., breast cancer, 2008 | 16 | Lower nagalase; claimed remission | Retracted; uncontrolled | | Yamamoto et al., colorectal cancer, 2008 | 8 | Lower nagalase; claimed tumour eradication | Retracted; questionable outcome assessment | | Yamamoto et al., prostate cancer, 2008 | 16 | Lower nagalase | Uncontrolled; inadequate confirmation | | Advanced cancer retrospective analysis, 2013 | 20 | Lower nagalase in 19 patients | Retrospective; mixed cancer types; unvalidated surrogate | The findings listed are what the authors claimed, not verified treatment success rates. ### 4.6 Why these studies are insufficient A cancer treatment has to improve outcomes that matter to patients: objective tumor shrinkage on validated imaging criteria, longer progression-free or overall survival, better symptoms, function or quality of life, and side effects that are acceptable relative to the benefit. Showing this usually requires a suitable patient population, outcome measures defined in advance, a standardized intervention and a comparison group. The GcMAF studies did not provide that kind of evidence. Small sample size was only part of the problem; the larger one was that small samples were combined with weak outcome measures and no reliable way to separate the effect of treatment from everything else. ## 5\. GcMAF and Infectious Diseases ### 5.1 HIV infection An early hypothesis held that GcMAF could help macrophages respond to HIV, on the theory that HIV-related nagalase activity blocks activation of vitamin D-binding protein. A 2009 paper by Yamamoto and colleagues claimed that GcMAF eliminated HIV infection in treated patients. That paper was later retracted, its claims have never been confirmed in rigorous trials, and there is no reliable evidence that GcMAF eradicates HIV or can replace antiretroviral therapy \[5\]. This matters because modern antiretroviral therapy can suppress HIV to undetectable levels, preserve immune function and halt disease progression. Swapping it for GcMAF would put patients at serious and avoidable risk. ### 5.2 Chronic viral infections GcMAF has also been promoted for chronic viral infections more broadly, since macrophages contribute to innate antiviral defense. But clearing a virus depends on viral replication, where the virus sits in the body, innate immune signaling, antigen-specific responses and the virus's own ways of persisting. A laboratory increase in macrophage activity is not evidence that GcMAF can clear a chronic infection. ### 5.3 COVID-19 During and after the COVID-19 pandemic, some proposed links between GcMAF, vitamin D-binding protein and the immune and inflammatory response to SARS-CoV-2\. These ideas may be mechanistically interesting, but there is no evidence that GcMAF prevents infection, reduces severe disease or improves survival, and it is not a substitute for evidence-based prevention or treatment. ## 6\. GcMAF in Autism and Neurological Disorders GcMAF has also been studied, and marketed, for autism and for conditions linked to neuroinflammation or altered immune activity. ### 6.1 Rationale for investigation Immune signaling plays a real role in the nervous system. Microglia, the brain's resident immune cells, belong to the same broad family as macrophages and take part in neural development, tissue maintenance and the response to injury. Some researchers have explored links between immune regulation, neuroinflammation, the endocannabinoid system and autism. None of this makes autism an immune disorder, or suggests that boosting macrophage activity would improve development. Autism is a varied neurodevelopmental condition with many biological contributors. ### 6.2 Laboratory research In 2014, Siniscalco and colleagues exposed macrophages derived from the blood of autistic participants to GcMAF in the laboratory and reported changes in endocannabinoid-related gene expression, cannabinoid receptor signalling and macrophage activation \[7\]. The work is relevant to immune-cell biology, but it did not test GcMAF in autistic people and says nothing about effects on communication, adaptive functioning or any other clinical outcome. ### 6.3 Clinical implications GcMAF has been sold for autism in some places despite the lack of reliable evidence. Using unapproved biological products in children raises further concerns: uncertain purity, possible immune reactions, and no validated dosing or long-term safety data. GcMAF is not an established treatment for autism. The same caution applies to claims about multiple sclerosis, chronic fatigue syndromes, Alzheimer's disease and other neurological conditions; the involvement of the immune system in a disease does not show that GcMAF can treat it. ## 7\. Safety and Potential Adverse Effects Sellers often describe GcMAF as a natural protein with few or no side effects. That argument does not hold up. Naturally occurring substances can cause serious harm when given in the wrong amounts, in altered forms or in contaminated preparations. ### 7.1 Limited safety data Some early studies reported no significant adverse effects, but trials with a few dozen participants cannot detect rare, delayed or long-term problems. A treatment can look well tolerated in 10 or 20 patients and still cause clinically significant harm in hundreds or thousands. Uncertain manufacturing quality also means safety findings for one preparation may not apply to another. ### 7.2 Potential safety concerns The table lists plausible or recognized risks of unapproved injectable biological products in general. It is not a verified list of GcMAF-specific adverse-event rates. | Potential risk | Explanation | | ---------------------------- | ------------------------------------------------------------------------- | | Allergic reactions | Foreign or modified proteins may trigger hypersensitivity | | Contamination | Poor manufacturing or handling may introduce microorganisms or endotoxins | | Injection-related infection | Non-sterile products or techniques may introduce pathogens | | Unintended inflammation | Immune modulation could produce undesirable inflammatory effects | | Product inconsistency | Different preparations may contain different protein forms or impurities | | Blood-derived material risks | Insufficient screening or processing may introduce additional hazards | | Treatment delay | Reliance on unproven therapy may postpone effective medical treatment | These uncertainties weigh especially heavily for people with cancer or weakened immunity. ### 7.3 The manufacturing problem GcMAF is not necessarily one chemically uniform substance. Manufacturers may start from different sources of vitamin D-binding protein and use different modification and purification methods, so products sold under the same name may not be biologically equivalent. For a protein therapy, the relevant quality attributes include identity, purity, glycosylation profile, biological activity, sterility, endotoxin levels, stability and batch-to-batch consistency. Without defined manufacturing standards, results from one preparation cannot be assumed to apply to another. Researchers working on GcMAF have said as much themselves. A 2020 paper in *Scientific Reports* observed that laboratories and clinics have each made their own GcMAF by their own procedures, which makes results hard to compare across groups, and set out to solve the problem by producing the protein recombinantly instead of from donated blood \[12\]. The authors expressed human Gc protein in serum-free suspension cultures of ExpiCHO-S cells and found, unexpectedly, that the cells secreted it already carrying only the single GalNAc residue, so no enzymatic trimming step was needed; the product could then be purified in one pass over a vitamin D affinity column, and it activated phagocytosis in a macrophage assay as strongly as the enzyme-treated version. A route of this kind matters because it removes two of the weakest links in the older preparations: human blood plasma of uncertain provenance as the starting material, and a hand-run de-glycosylation step that varied between laboratories. This is a production method, not a treatment. The paper reports no animal or human results, its activity data come from a single phagocytosis assay in a cell line, and several authors are named on a patent application for the method. What it offers the field is the possibility of a consistent, characterized preparation, which is a precondition for meaningful clinical testing rather than a substitute for it. ## 8\. Regulatory History and Controversy GcMAF has a history of regulatory action, particularly in the United Kingdom. In February 2015 the Medicines and Healthcare products Regulatory Agency (MHRA) warned against unlicensed GcMAF made at a facility in Cambridgeshire. Inspectors found serious problems with production conditions and discovered that the starting material was blood plasma not intended for use in humans. The MHRA advised anyone who had bought the product to speak to their doctor \[10\]. Enforcement continued after the warning. According to UK government records, more than 10,000 vials were seized, and an individual who had marketed GcMAF as a treatment for serious diseases faced criminal proceedings and confiscation orders. These events raise three separate concerns: claims of effectiveness need reliable evidence behind them; injectable biological products require strict quality control; and selling an unproven treatment to seriously ill people is especially dangerous when it is offered as an alternative to effective care. Action against particular manufacturers does not disprove every possible biological effect of GcMAF, but it does show that commercially available preparations cannot be assumed to be safe, effective or properly made. ## 9\. Recent Research and Future Developments Despite the weaknesses of the early literature, research on vitamin D-binding protein, protein glycosylation and macrophage regulation remains scientifically worthwhile. ### 9.1 The importance of glycosylation Glycosylation, the attachment of carbohydrate chains to proteins and lipids, affects how proteins fold, bind receptors, circulate in the blood and take part in immune signaling. Mass spectrometry and glycoproteomics now allow these modifications to be studied far more precisely than was possible during the first GcMAF studies, and they have already corrected the original picture of the Gc protein's sugar chain \[12\]. That matters because small differences in glycosylation can change a protein's activity. A basic unresolved question is whether the effects attributed to GcMAF come from a single, reproducibly identifiable molecule or from variable mixtures of modified proteins and other components. Recombinant expression, which yields a defined product without blood-derived starting material or a manual trimming step, is one way to make that question answerable. ### 9.2 Emerging GcMAF research A 2026 paper in *Immunology* describes a glycosylation-focused approach called GcMAF2.0, including proposed interactions with the macrophage receptor CLEC10A \[11\]. This work tries to address some of the earlier problems: poor molecular characterization, inconsistent manufacturing, and difficulty separating a specific protein effect from general immune stimulation. It should be read as emerging research, not clinical validation. Even if a well-defined preparation reliably changes macrophage function, several questions remain: - Does the effect occur at concentrations achievable in humans? - Does it produce a clinically meaningful benefit? - Can it promote helpful immune activity without causing harmful inflammation? - Does it improve outcomes compared with existing treatments? - Are its safety and manufacturing consistent enough for clinical development? Until these are answered, newer formulations cannot be considered proven simply because they carry the GcMAF name. ### 9.3 Relationship to modern cancer immunotherapy Using the immune system against cancer is now a central part of oncology. Proven approaches include immune checkpoint inhibitors, certain therapeutic monoclonal antibodies and cell therapies such as CAR-T for some cancers, and researchers are exploring engineered macrophages, macrophage-directed drugs and ways to reshape the tumor microenvironment. The success of these treatments does not lend support to GcMAF. Each intervention has to prove its own safety and effectiveness. ## 10\. What Would Be Needed to Establish GcMAF as a Legitimate Therapy? A credible development program would need to proceed in stages: 1. **Molecular characterisation:** identify the active substance, distinguish the relevant glycoforms and standardize manufacturing. 2. **Reproducible preclinical work:** pin down the mechanisms behind the macrophage response, with controls for impurities and non-specific inflammation. 3. **Early-phase human trials:** establish preliminary safety, pharmacokinetics, biological activity and dose range. 4. **Randomized controlled trials:** test effectiveness in a specific disease using validated outcomes. In cancer, that means tumor response, progression-free survival, overall survival and quality of life. 5. **Independent replication:** other research groups must reproduce the findings before wider clinical use is justified. Each step is needed because a treatment can have promising biological effects and still fail to improve patients' health. ## 11\. Evidence Quality: An Integrated Assessment This is a qualitative judgement based on the research reviewed here, not a formal GRADE assessment. | Area | Strength of evidence | Comment | | -------------------------------- | -------------------- | ----------------------------------- | | Experimental macrophage activity | Preliminary | Some supportive preclinical studies | | Defined mechanism in humans | Uncertain | Substantial mechanistic uncertainty | | Anticancer clinical efficacy | Insufficient | Not established | | Antiviral clinical efficacy | Insufficient | Not established | | Neurological or autism efficacy | Insufficient | Not established | | Long-term safety | Insufficient | Inadequately studied | The key finding of this review is the gap between preliminary laboratory evidence and weak clinical evidence. A biologically plausible treatment is not necessarily an effective one. At the same time, an incomplete evidence base does not justify claims of certain benefit or of certain failure. The right response is to state the uncertainty clearly and ask whether well-designed studies could resolve it. ## 12\. Frequently Asked Questions **Does GcMAF activate macrophages?** Some preparations have increased measures of macrophage activity in laboratory experiments. How large, specific and clinically meaningful these effects are in humans has not been consistently shown. **Does GcMAF cure cancer?** No reliable clinical evidence shows that it does. Several widely cited studies claiming to have eradicated cancer were later retracted or criticized for poor methods. **Can GcMAF strengthen the immune system?** "Strengthening the immune system" is a vague idea. GcMAF may affect certain immune-cell functions in experiments, but that does not show an overall improvement in immune protection or health. **Is GcMAF naturally produced in the body?** Vitamin D-binding protein is. Certain glycosylated forms have been proposed to help regulate macrophages, but their full physiological role, and whether manufactured GcMAF is equivalent to them, remain uncertain. **Is GcMAF safer than chemotherapy?** There is not enough evidence to compare them. Chemotherapy carries known risks, but its benefits and side effects have been characterized through extensive clinical testing. GcMAF has no comparable safety or efficacy data. **Could GcMAF eventually become a useful treatment?** It is possible that a carefully characterized protein derived from vitamin D-binding protein could have therapeutic uses. Showing this would take high-quality studies replicated by independent groups. ## 13\. Conclusion GcMAF is an interesting but deeply contested episode in immunotherapy research. Its theoretical basis draws on real biology (vitamin D-binding protein, glycosylation, macrophage function and immune regulation), and laboratory studies reporting effects on phagocytosis and other cellular responses justify further work on mechanism. The leap from those observations to claims of treating serious disease is where things went wrong. The early clinical studies were small, poorly controlled, dependent on an experimental biomarker and weak on verifying outcomes, and the retraction of several key papers has badly undermined the claims of dramatic success. The proposed role of nagalase, both as a suppressor of macrophage activation and as a measure of tumor burden, has not been validated for clinical use. Nor can safety concerns about unlicensed biological products be waved away because the starting protein occurs naturally in the body; manufacturing quality, composition, immune effects and long-term risks all need proper evaluation. Newer work using glycoproteomics and macrophage-directed approaches may clarify whether specific GcMAF-related molecules have useful properties. As of October 2026, however, the evidence does not establish GcMAF as a safe and effective treatment for cancer, HIV, autism or any other major disease. It should be treated as a subject of investigation, not a validated therapy, and anyone considering a commercial product should speak to a qualified clinician, especially if it is being offered in place of established treatment. Whatever value future GcMAF research has will depend not on how many diseases it is claimed to treat or how dramatic past claims were, but on reproducible molecular findings, well-controlled human studies and measurable improvements in patient outcomes. ## 14\. References and Further Reading The list includes original studies, critical assessments, regulatory notices and recent research. Retracted papers are marked. 1. Yamamoto N., et al. (1996). Structural definition of a potent macrophage activating factor derived from vitamin D3-binding protein with adjuvant activity for antibody production. *Molecular Immunology*, 33(15), 1157–1164\. Foundational preclinical study. [https://pubmed.ncbi.nlm.nih.gov/9070663/](https://pubmed.ncbi.nlm.nih.gov/9070663/?ref=foodconsumer.org) 2. Yamamoto N., et al. (2008). Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). *International Journal of Cancer*, 122, 461–467\. **Retracted 2014.** [https://pubmed.ncbi.nlm.nih.gov/17935130/](https://pubmed.ncbi.nlm.nih.gov/17935130/?ref=foodconsumer.org) 3. Yamamoto N., et al. (2008). Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. *Cancer Immunology, Immunotherapy*, 57, 1007–1016\. **Retracted 2014.** [https://pubmed.ncbi.nlm.nih.gov/18058096/](https://pubmed.ncbi.nlm.nih.gov/18058096/?ref=foodconsumer.org) 4. Yamamoto N., et al. (2008). Immunotherapy for prostate cancer with Gc protein-derived macrophage-activating factor, GcMAF. *Translational Oncology*, 1(2), 65–72\. [https://pubmed.ncbi.nlm.nih.gov/18633461/](https://pubmed.ncbi.nlm.nih.gov/18633461/?ref=foodconsumer.org) 5. Yamamoto N., et al. (2009). Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF). *Journal of Medical Virology*, 81(1), 16–26\. **Retracted 2014.** [https://pubmed.ncbi.nlm.nih.gov/19031451/](https://pubmed.ncbi.nlm.nih.gov/19031451/?ref=foodconsumer.org) 6. GC protein-derived macrophage-activating factor decreases α-N-acetylgalactosaminidase levels in advanced cancer patients (2013). *OncoImmunology*. Uncontrolled retrospective study of 20 patients. [https://pubmed.ncbi.nlm.nih.gov/24179708/](https://pubmed.ncbi.nlm.nih.gov/24179708/?ref=foodconsumer.org) 7. Siniscalco D., et al. (2014). The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages. *Journal of Neuroinflammation*, 11, 78\. [https://pubmed.ncbi.nlm.nih.gov/24739187/](https://pubmed.ncbi.nlm.nih.gov/24739187/?ref=foodconsumer.org) 8. Cancer Research UK. Cancer cured for good? Gc-MAF and the miracle cure. Critique of the methods used in the early cancer studies. [https://news.cancerresearchuk.org/2008/12/03/cancer-cured-for-good-gc-maf-and-the-miracle-cure/](https://news.cancerresearchuk.org/2008/12/03/cancer-cured-for-good-gc-maf-and-the-miracle-cure/?ref=foodconsumer.org) 9. Cancer Council Australia. Can GcMAF rebuild the immune system to eradicate early-stage cancer? [https://www.cancer.org.au/iheard/can-gcmaf-rebuild-the-immune-system-to-eradicate-early-stage-cancer](https://www.cancer.org.au/iheard/can-gcmaf-rebuild-the-immune-system-to-eradicate-early-stage-cancer?ref=foodconsumer.org) 10. UK Medicines and Healthcare products Regulatory Agency (2015). Regulator warns against GcMAF made in unlicensed facility in Cambridgeshire. [https://www.gov.uk/government/news/regulator-warns-against-gcmaf-made-in-unlicensed-facility-in-cambridgeshire](https://www.gov.uk/government/news/regulator-warns-against-gcmaf-made-in-unlicensed-facility-in-cambridgeshire?ref=foodconsumer.org) 11. Pokushalov et al. (2026). Precision glyco-modulated GcMAF2.0 targets CLEC10A to bidirectionally re-wire macrophage states: cross-species evidence, mechanistic omics and translational horizons. *Immunology*. Its claims require independent assessment and clinical validation. [https://doi.org/10.1111/imm.70132](https://doi.org/10.1111/imm.70132?ref=foodconsumer.org) 12. Nabeshima, Y., Abe, C., Kawauchi, T., Hiroi, T., Uto, Y., & Nabeshima**,** Y. (2020). Simple method for large-scale production of macrophage activating factor GcMAF. *Scientific Reports*, 10, 19122\. Recombinant production in ExpiCHO-S cells; in vitro activity data only, no animal or clinical results. [https://doi.org/10.1038/s41598-020-75571-y](https://doi.org/10.1038/s41598-020-75571-y?ref=foodconsumer.org) *Scope: This is a critical narrative review of selected evidence, not a registered systematic review or meta-analysis. It is intended for scientific and educational purposes and is not individual medical advice.*